66th Annual American Society of Hematology Annual Meeting and Exposition – (AL Amyloidosis) – November 2024
Eyal Lebel, Nathalie Asherie, Miri Assayag, Shlomo Elias, MD, PhD, Sigal Grisariu, MD, Batia Avni, MD, Shlomit Kfir-Erenfeld, Tali Dubnikov-Sharon, Rivka Alexander-Shani, Nomi Bessig, Alaa Shehadeh, Aseel Ishtay, Shelly Pimienta, Vladimir Vaistein, Eran Zimran, Marjorie Pick, Yael C. Cohen, Irit Avivi Mazza, Cyrille Cohen, Polina Stepensky and Moshe E Gatt, MD. Efficacy and Safety of Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) for the Treatment of Relapsed and Refractory AL Amyloidosis. 66th ASH Annual Meeting and Exposition, San Diego, CA, December 9, 2024.
ASGCT – American Society of Gene & Cell Therapy — 27th Annual Meeting – May 10, 2024
M. Assayag, N. Asherie, S. Kfir-Erenfeld, Eyal Lebel, S. Grisariu, B. Avni, T. Dubnikov-Sharon1, S. Elias, M. Gatt, P. Stepensky. Academic BCMA-CART Cells HBI0101 (NXC-201), a Promising Approach for the Treatment of LC Amyloidosis. American Society of Gene & Cell Therapy 27th Annual Meeting. May 10, 2024.
ISA – XIX International Symposium on Amyloidosis (International Society of Amyloidosis) Presentation
E. Lebel, S. Kfir Erenfeld, N. Asherie, S. Grisariu, B. Avni, S. Elias, M. Assayag, T. Dubnikov, N. Zalcman, M. Pick, E. Zimran, C. Cohen, P. Stepensky, M.E. Gatt. Efficacy and Safety of Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (NXC-201) for the Treatment of Relapsed and Refractory AL amyloidosis. International Society of Amyloidosis. May, 2024.
ASH – 65th Annual American Society of Hematology Annual Meeting and Exposition (AL Amyloidosis) – Dec 10, 2023
Lebel, S. Kfir Erenfeld, N. Asherie, S. Grisariu, B. Avni, S. Elias, M. Assayag, T. Dubnikov, N. Zalcman, M. Pick, E. Zimran, Y. Cohen, I. Avivi, C. Cohen, P. Stepensky, M.E. Gatt. Feasibility of a Novel Academic Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis, 65th ASH Annual Meeting and Exposition, San Diego, CA. Dec 10 2023
ASH – 65th Annual American Society of Hematology Annual Meeting and Exposition – (AL Amyloidosis) – October 2023
Lebel, S. Kfir Erenfeld, N. Asherie, S. Grisariu, B. Avni, S. Elias, M. Assayag, T. Dubnikov, N. Zalcman, M. Pick, E. Zimran, Y. Cohen, I. Avivi, C. Cohen, P. Stepensky, M.E. Gatt. Feasibility of a Novel Academic Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis, 65th ASH Annual Meeting and Exposition, San Diego, CA. October 2023
IMS – International Myeloma Society – 20th Annual Meeting -Oral Presentation (AL Amyloidosis) – Sep 27-30, 2023
Lebel, S. Kfir Erenfeld, N. Asherie, S. Grisariu, B. Avni, S. Elias, M. Assayag, T. Dubnikov, N. Zalcman, M. Pick, E. Zimran, Y. Cohen, I. Avivi, C. Cohen, P. Stepensky, M.E. Gatt. Feasibility of a Novel Academic Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis, International Myeloma Society 20th Annual Meeting. 2023 Sep 27-30.
ASGCT – American Society of Gene & Cell Therapy — 29th Annual Meeting – May 19, 2023
ASGCT – American Society of Gene & Cell Therapy — 29th Annual Meeting – May 19, 2023
ASGCT – American Society of Gene & Cell Therapy — 29th Annual Meeting – May 19, 2023
Asherie N., Kfir-Erenfeld S., Lebel E., Assayag M., Grisariu S., Avni B., Gatt ME, Stepensky, P. BCMA-Targeted CART (HBI0101), a Safe and Efficacious Novel Modality of Treatment for Light Chain Amyloidosis (AL) Patients. Late Breaking Abstract. ASGCT – American Society of Gene & Cell Therapy 29 th Annual Meeting. May 19, 2023.
Phase 1 – AL Amyloidosis
Kfir-Erenfeld S, Asherie N, Grisariu S, Avni B, Zimran E, Assayag M, Sharon TD, Pick M, Lebel E, Shaulov A, Cohen YC, Avivi I, Cohen CJ, Stepensky P, Gatt ME. Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis. Clin Cancer Res. 2022 Dec 1;28(23):5156-5166. doi: 10.1158/1078-0432.CCR-22-0637. PMID: 36107221.